Maze Therapeutics, Inc. (MAZE): R&D Expense
$108.45M
Year ended 2025-12-31
$121.85M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $108.45M | +29.9% | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $83.50M | n/a | 2026-03-25, From 2024-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | 2025-12-31 | $108.45M | +29.9% |
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $208.44M | +12.9% |
| Allogene Therapeutics, Inc. (ALLO) | 2025-12-31 | $150.15M | -21.9% |
| Sana Biotechnology, Inc. (SANA) | 2025-12-31 | $131.98M | -38.8% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $20.71M | +114.8% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $104.24M | -5.8% |
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | $187.40M | +31.1% |
| Kodiak Sciences Inc. (KOD) | 2025-12-31 | $182.37M | +44.6% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $141.50M | +16.4% |
Compare MAZE, SRRK, ALLO, SANA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗